Literature DB >> 2971382

Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate.

J P Bonjour1, J Philippe, G Guelpa, A Bisetti, R Rizzoli, A Jung, S Rosini, J A Kanis.   

Abstract

Increased bone resorption (BR) and increased renal tubular reabsorption of calcium (TRCa) may both be involved in the pathogenesis of hypercalcemia of malignancy (HM). We have evaluated the relative importance of these two mechanisms in 33 patients with HM after extracellular volume expansion and after single infusion of clodronate (C12MDP: 500 mg iv over 8 h). The fasting urine Ca/creatinine ratio was taken as an index of BR (BRI). An index of TRCa was calculated (TRCaI) from a nomogram based on the relationship between urine Ca excretion per unit of glomerular filtration rate and plasma Ca (PCa). Mean (+/- SEM) PCa fell from 3.29 +/- 0.07 to 2.69 +/- 0.05 mmol/l three days after C12MDP (n = 33, p less than 0.001), a response similar to that obtained with repeated daily iv injections of 500 to 1000 mg C12MDP. The pathogenesis of hypercalcemia varied according to the type of neoplasm. BRI was the highest in multiple myeloma and breast tumors. TRCaI was markedly increased in squamous-cells lung, bladder, kidney and liver carcinomas, reaching levels observed in primary hyperparathyroidism. TRCaI was normal in most cases of multiple myeloma. Breast tumors appeared to be heterogeneous with respect to TRCaI. The fall in PCa in response to a single infusion of C12MDP was usually most marked in cancer patients with elevated BRI and normal TRCaI. It was very modest in patients with high TRCaI and slightly elevated BRI. In conclusion, this study confirms that stimulation of bone resorption is not the only mechanism of the maintenance of hypercalcemia of malignancy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2971382     DOI: 10.1016/8756-3282(88)90001-4

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  20 in total

Review 1.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 2.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

3.  Hypercalcaemia in malignancy.

Authors:  S H Ralston; S J Gallacher; U Parel; I T Boyle
Journal:  BMJ       Date:  1989-07-15

4.  Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis.

Authors:  R Rizzoli; T Chevalley; D O Slosman; J P Bonjour
Journal:  Osteoporos Int       Date:  1995-01       Impact factor: 4.507

Review 5.  Bisphosphonates and the treatment of bone disease in the elderly.

Authors:  A Johansen; M Stone; F Rawlinson
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

Review 6.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 7.  Hypercalcemia in malignancy.

Authors:  G J Strewler; R A Nissenson
Journal:  West J Med       Date:  1990-12

8.  [Pamidronate in the treatment of tumor-associated hypercalcemia].

Authors:  M Pecherstorfer; S Janisch; C Marosi; C Wogritsch; C Bosse; W Schratzberger; E Gerber; A Fortelny; R Lenzhofer; H Rainer
Journal:  Klin Wochenschr       Date:  1991-10-02

9.  Zinc increases the effects of essential amino acids-whey protein supplements in frail elderly.

Authors:  A Rodondi; P Ammann; S Ghilardi-Beuret; R Rizzoli
Journal:  J Nutr Health Aging       Date:  2009-06       Impact factor: 4.075

Review 10.  Medical treatment of tumor-induced hypercalcemia and tumor-induced osteolysis: challenges for future research.

Authors:  J J Body
Journal:  Support Care Cancer       Date:  1993-01       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.